[ENTA] Enanta Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 34.53 Change: 1.51 (4.57%)
Ext. hours: Change: 0 (0%)

chart ENTA

Refresh chart

Strongest Trends Summary For ENTA

ENTA is in the medium-term down -15% below S&P in 2 months and down -41% below S&P in 5 months. In the long-term up 103% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 36.42% Sales Growth - Q/Q-25.98% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA47.08% ROE51.63% ROI
Current Ratio8.98 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin82.62% Net Profit Margin64.48% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.26 M Cash From Investing Activities-100.46 M Cash From Operating Activities93.25 M Gross Profit
Net Profit28.75 M Operating Profit48.56 M Total Assets245.88 M Total Current Assets177.78 M
Total Current Liabilities19.79 M Total Debt180 K Total Liabilities21.67 M Total Revenue57.37 M
Technical Data
High 52 week105.66 Low 52 week57.95 Last close59.48 Last change2.09%
RSI24.08 Average true range3.15 Beta1.05 Volume182.38 K
Simple moving average 20 days-6.19% Simple moving average 50 days-11.99% Simple moving average 200 days-28.44%
Performance Data
Performance Week2.41% Performance Month-14.89% Performance Quart-27.21% Performance Half-35.06%
Performance Year-20.36% Performance Year-to-date-16.02% Volatility daily3.86% Volatility weekly8.64%
Volatility monthly17.71% Volatility yearly61.35% Relative Volume295.56% Average Volume208.95 K
New High0.99% New Low

News

2019-11-17 08:42:54 | The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

2019-11-14 10:30:03 | Analysts Estimate Enanta Pharmaceuticals ENTA to Report a Decline in Earnings: What to Look Out for

2019-11-11 10:21:50 | Is Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA 14% ROE Worse Than Average?

2019-11-11 07:30:00 | Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019

2019-11-05 16:00:00 | Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

2019-10-27 22:29:08 | Enanta Pharmaceuticals Inc ENTA: Hedge Funds In Wait-and-See Mode

2019-10-21 16:00:00 | Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference

2019-10-12 10:03:32 | Is Enanta Pharmaceuticals's NASDAQ:ENTA Share Price Gain Of 145% Well Earned?

2019-10-03 07:30:00 | New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions p<0.001 in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay

2019-09-26 16:16:41 | This Biotech Stock Just Careened Toward Its Lowest Point In Nearly 2 Years

2019-09-26 11:40:03 | Enanta's Stock Down Despite NASH Drug Meeting Goal in Study

2019-09-26 07:54:44 | The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

2019-09-25 16:28:46 | UPDATE 1-Enanta Pharma's NASH drug meets mid-stage study goal

2019-09-25 16:12:44 | Enanta Pharma's liver disease drug meets mid-stage study goal

2019-09-25 16:00:00 | Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH

2019-09-12 09:48:04 | Is Enanta Pharmaceuticals NASDAQ:ENTA A Risky Investment?

2019-09-10 07:30:00 | New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019

2019-08-21 07:30:00 | Enanta Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference

2019-08-13 13:24:08 | Enanta Pharmaceuticals, Inc. NASDAQ:ENTA: What Does Its Beta Value Mean For Your Portfolio?

2019-08-07 12:37:52 | Enanta Pharmaceuticals, Inc. ENTA Q2 2019 Earnings Call Transcript

2019-08-07 02:05:39 | Edited Transcript of ENTA earnings conference call or presentation 6-Aug-19 8:30pm GMT

2019-08-06 17:55:09 | Enanta Pharmaceuticals ENTA Q3 Earnings Surpass Estimates

2019-08-06 16:00:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2019

2019-08-02 08:51:00 | Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ glecaprevir/pibrentasvir to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis

2019-07-30 10:38:02 | Enanta Pharmaceuticals ENTA Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

2019-07-15 07:30:00 | Enanta Pharmaceuticals to Host Conference Call on August 6 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2019

2019-07-11 09:00:01 | Enanta Pharmaceuticals ENTA Upgraded to Strong Buy: Here's What You Should Know

2019-07-08 07:30:00 | Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus HBV

2019-06-14 14:06:11 | Enanta's Respiratory Virus Drug Aces Midstage Study

2019-06-14 11:12:07 | How Much Did Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA CEO Pocket Last Year?

2019-06-14 09:51:28 | UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial

2019-06-14 06:00:00 | Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus RSV

2019-06-10 16:00:00 | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

2019-06-10 08:00:00 | AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies

2019-05-30 08:00:00 | AbbVie's MAVIRET™ now listed in New Brunswick

2019-05-15 11:11:03 | Do Enanta Pharmaceuticals's NASDAQ:ENTA Earnings Warrant Your Attention?

2019-05-14 16:01:00 | Enanta Pharmaceuticals to Present at Upcoming Investor Conference

2019-05-08 00:02:11 | Edited Transcript of ENTA earnings conference call or presentation 7-May-19 8:30pm GMT

2019-05-07 21:00:10 | Enanta Pharmaceuticals, Inc. ENTA Q2 2019 Earnings Call Transcript

2019-05-07 17:25:09 | Enanta Pharmaceuticals ENTA Beats Q2 Earnings Estimates

2019-05-07 16:16:26 | Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot

2019-05-07 16:00:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019

2019-05-02 14:22:17 | Here’s What Hedge Funds Think About Enanta Pharmaceuticals Inc ENTA

2019-04-30 10:32:02 | Analysts Estimate Enanta Pharmaceuticals ENTA to Report a Decline in Earnings: What to Look Out for

2019-04-22 16:30:00 | Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019

2019-04-15 09:40:02 | VKTX or ENTA: What to Expect from Revenue Growth in 2019

2019-04-15 08:05:54 | What Are Analysts Recommending for VKTX and ENTA?

2019-04-11 10:13:00 | Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus and Non-Alcoholic Steatohepatitis at The International Liver Congress™ 2019

2019-04-11 09:00:00 | AbbVie's MAVIRET™ now reimbursed in Quebec

2019-04-05 15:32:02 | Can You Imagine How Chuffed Enanta Pharmaceuticals's NASDAQ:ENTA Shareholders Feel About Its 216% Share Price Gain?